Jose F Huizar1, Susan G Fisher2, Frederick V Ramsey2, Karoly Kaszala3, Alex Y Tan3, Hans Moore4, Jayanthi N Koneru5, Jordana Kron5, Santosh K Padala5, Kenneth A Ellenbogen5, Steven N Singh4. 1. Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA; Virginia Commonwealth University/Pauley Heart Center, Richmond, Virginia, USA. Electronic address: jfhuizar@vcuhealth.org. 2. Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA. 3. Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA; Virginia Commonwealth University/Pauley Heart Center, Richmond, Virginia, USA. 4. Washington Veterans Affairs Medical Center, Washington, DC, USA. 5. Virginia Commonwealth University/Pauley Heart Center, Richmond, Virginia, USA.
Abstract
OBJECTIVES: This study sought to assess the rate and outcomes of premature ventricular contractions (PVC)-cardiomyopathy from the CHF-STAT (Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure) trial, a population with cardiomyopathy (left ventricular [LV] ejection fraction of <40%) and frequent PVCs (>10 PVCs per hour). BACKGROUND: PVCs are associated with heart failure and PVC-cardiomyopathy. The prevalence of PVC-cardiomyopathy and outcome benefits of PVC suppression are not clear. METHODS: A secondary analysis of the CHF-STAT study was performed to compare the rate of successful PVC suppression (≥80% PVC reduction), LV recovery (defined as improvement in LV ejection fraction of ≥10% points), and PVC-cardiomyopathy between amiodarone and placebo groups at 6 months. PVC-cardiomyopathy was defined if both PVC reduction of ≥80% and LV ejection fraction improvement of ≥10% were present at 6 months. Cardiac events (death or resuscitated cardiac arrest) were compared between PVC-cardiomyopathy versus non-PVC-cardiomyopathy during a 5-year follow-up. RESULTS: The rates of successful PVC suppression and LV recovery were significantly higher in the amiodarone (72% and 39%, respectively) when compared to the placebo group (12% and 16%, respectively; p < 0.001), regardless of cardiomyopathy etiology. PVC-cardiomyopathy was present in 29% and 1.8% of patients in the amiodarone and placebo groups, respectively (p < 0.001). Similar PVC-cardiomyopathy rates were found in ischemic (24% amiodarone vs. 2% placebo; p < 0.001) and nonischemic populations (41% amiodarone vs. 1.5% placebo; p < 0.001). Death and resuscitated cardiac arrest were significantly lower in patients with PVC-cardiomyopathy and those treated with amiodarone. CONCLUSIONS: The overall prevalence of PVC-cardiomyopathy in the CHF-STAT study was significant regardless of ischemic substrate (29%, overall population; 41%, nonischemic cardiomyopathy). Treatment of PVC-cardiomyopathy with amiodarone is likely to improve survival in this high-risk population. Published by Elsevier Inc.
OBJECTIVES: This study sought to assess the rate and outcomes of premature ventricular contractions (PVC)-cardiomyopathy from the CHF-STAT (Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure) trial, a population with cardiomyopathy (left ventricular [LV] ejection fraction of <40%) and frequent PVCs (>10 PVCs per hour). BACKGROUND: PVCs are associated with heart failure and PVC-cardiomyopathy. The prevalence of PVC-cardiomyopathy and outcome benefits of PVC suppression are not clear. METHODS: A secondary analysis of the CHF-STAT study was performed to compare the rate of successful PVC suppression (≥80% PVC reduction), LV recovery (defined as improvement in LV ejection fraction of ≥10% points), and PVC-cardiomyopathy between amiodarone and placebo groups at 6 months. PVC-cardiomyopathy was defined if both PVC reduction of ≥80% and LV ejection fraction improvement of ≥10% were present at 6 months. Cardiac events (death or resuscitated cardiac arrest) were compared between PVC-cardiomyopathy versus non-PVC-cardiomyopathy during a 5-year follow-up. RESULTS: The rates of successful PVC suppression and LV recovery were significantly higher in the amiodarone (72% and 39%, respectively) when compared to the placebo group (12% and 16%, respectively; p < 0.001), regardless of cardiomyopathy etiology. PVC-cardiomyopathy was present in 29% and 1.8% of patients in the amiodarone and placebo groups, respectively (p < 0.001). Similar PVC-cardiomyopathy rates were found in ischemic (24% amiodarone vs. 2% placebo; p < 0.001) and nonischemic populations (41% amiodarone vs. 1.5% placebo; p < 0.001). Death and resuscitated cardiac arrest were significantly lower in patients with PVC-cardiomyopathy and those treated with amiodarone. CONCLUSIONS: The overall prevalence of PVC-cardiomyopathy in the CHF-STAT study was significant regardless of ischemic substrate (29%, overall population; 41%, nonischemic cardiomyopathy). Treatment of PVC-cardiomyopathy with amiodarone is likely to improve survival in this high-risk population. Published by Elsevier Inc.
Authors: Timir S Baman; Dave C Lange; Karl J Ilg; Sanjaya K Gupta; Tzu-Yu Liu; Craig Alguire; William Armstrong; Eric Good; Aman Chugh; Krit Jongnarangsin; Frank Pelosi; Thomas Crawford; Matthew Ebinger; Hakan Oral; Fred Morady; Frank Bogun Journal: Heart Rhythm Date: 2010-03-27 Impact factor: 6.343
Authors: Andrea K Y Lee; Jason Andrade; Nathaniel M Hawkins; George Alexander; Matthew T Bennett; Shanta Chakrabarti; Zachary W Laksman; Andrew Krahn; John A Yeung-Lai-Wah; Marc William Deyell Journal: Heart Date: 2019-05-29 Impact factor: 5.994
Authors: Surksha Sirichand; Ammar M Killu; Deepak Padmanabhan; David O Hodge; Alanna M Chamberlain; Peter A Brady; Suraj Kapa; Peter A Noseworthy; Douglas L Packer; Thomas M Munger; Bernard J Gersh; Christopher J McLeod; Win-Kuang Shen; Yong-Mei Cha; Samuel J Asirvatham; Paul A Friedman; Siva K Mulpuru Journal: Circ Arrhythm Electrophysiol Date: 2017-02
Authors: Jonathan Potfay; Karoly Kaszala; Alex Y Tan; Adam P Sima; John Gorcsan; Kenneth A Ellenbogen; Jose F Huizar Journal: Circ Arrhythm Electrophysiol Date: 2015-08-21
Authors: Jose F Huizar; Karoly Kaszala; Jonathan Potfay; Anthony J Minisi; Edward J Lesnefsky; Antonio Abbate; Eleonora Mezzaroma; Qun Chen; Rakesh C Kukreja; Nicholas N Hoke; Leroy R Thacker; Kenneth A Ellenbogen; Mark A Wood Journal: Circ Arrhythm Electrophysiol Date: 2011-05-16
Authors: Li Zhong; Ying-Hsiang Lee; Xin-Miao Huang; Samuel J Asirvatham; Win-Kuang Shen; Paul A Friedman; David O Hodge; Joshua P Slusser; Zhi-Yuan Song; Douglas L Packer; Yong-Mei Cha Journal: Heart Rhythm Date: 2013-10-22 Impact factor: 6.343
Authors: Gurukripa N Kowlgi; Alex Y Tan; Karoly Kaszala; Michael C Kontos; Pedro Lozano; Kenneth A Ellenbogen; Jose F Huizar Journal: Front Cardiovasc Med Date: 2022-08-24
Authors: Juan Torrado; Gurukripa N Kowlgi; Rafael J Ramirez; Jaime Balderas-Villalobos; Daniel Jovin; Chandler Parker; Evani Om; Sergei Airapetov; Karoly Kaszala; Alex Y Tan; Kenneth A Ellenbogen; Jose F Huizar Journal: Heart Rhythm O2 Date: 2021-01-08